HUTCHMED (00013) Initiates Global Study of KRAS-EGFR Antibody-Drug Conjugate HMPL-A830 for the Treatment of Solid Tumors

Zhito Finance APP news: Hutchison MediPharma (00013) announced the launch of the Phase Ia portion of a global clinical trial of HMPL-A830 for the treatment of unresectable advanced or metastatic solid tumors. The first patient received the first dose of treatment in China on September 24, 2026.